New R Series Defibrillators with EtCO2 and NIBP and Temperature Management Solutions Showcased by ZOLL at American Heart Association Scientific Sessions

Zoll Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of medical devices and related software solutions, today announced that the R Series^® defibrillators with new monitoring capability added as well as its new intravascular temperature management solutions are being exhibited in Booth #1417 at the American Heart Association Scientific Sessions 2009 November 15-17^th at the Orange County Convention Center in Orlando.

ZOLL’s R Series Code-Ready^® Defibrillators, the original ALS and the newer R Series Plus, now offer mainstream capnography (EtCO₂) and non-invasive blood pressure (NIBP) options. These additional monitoring parameters assist rescuers in monitoring of critically ill patients and are useful before, during, and after a cardiac arrest. The R Series is designed to extend "Simple, Smart, Ready” defibrillation to every hospital department with advanced, cost-effective solutions for resuscitation. The R Series ALS is the most advanced ALS defibrillator available with networking capabilities and See-Thru CPR^®. The R Series Plus, which has both AED and ALS capabilities, also has networking capabilities and See-Thru CPR. R Series Plus is an easy-to-use AED that becomes a manual defibrillator at the touch of a button. Like all other ZOLL defibrillators, these models provide the Real CPR Help^® feature.

All R Series defibrillators use the same uniform operating system common to all ZOLL defibrillators. The cables, paddles, batteries, handles, and electrodes are also common to ensure clinicians won’t encounter a mismatch in a time of crisis. In addition, R Series ALS and Plus models can use wireless networking to ensure code-readiness.

New to ZOLL is Intravascular Temperature Management (IVTM^™). These systems offer health care providers the power and control they need to rapidly, safely, and effectively manage the core body temperature of critically ill or surgical patients. The Thermogard XP^®Advanced Temperature Management System delivers accurate, easy-to-use and cost-effective control for both cooling and warming applications. A range of endovascular catheters for cooling and warming also incorporate central venous infusion capabilities.

Also new to the ZOLL exhibit is the PocketCPR^® for the iPhone^®, an application which provides CPR training with real-time feedback. The application provides clear visual and audio step-by-step coaching on CPR performance and includes the initial steps to follow in the Chain of Survival. Attendees who take the CPR test on either the AED Plus^® or AED Pro^®, or listen to a product demo, will be able to download the PocketCPR^® application onto their iPhone or iPod Touch.

Additional products and technologies on display include:

• The AutoPulse^® Non-invasive Cardiac Support Pump which provides CPR chest compressions when the heart is no longer effectively circulating blood due to ventricular fibrillation or cardiac standstill. It features an easy-to-use, load-distributing LifeBand^® that squeezes the entire chest, improving blood flow to the heart and brain during sudden cardiac arrest (SCA). The AutoPulse may offer a significant advantage over manual CPR, moving blood more consistently than human providers. The device delivers high-quality, uninterrupted chest compressions to maintain myocardial and cerebral perfusion. Additionally, it offers the benefit of freeing up clinicians to focus on other life-saving interventions.
• The LifeVest^® Wearable Defibrillator, worn by patients at risk of SCA, provides protection during a patient’s changing condition and when permanent SCA risk has not been established. The LifeVest allows a patient’s physician time to assess their long-term arrhythmic risk and make appropriate plans. The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm. The LifeVest does not require bystander intervention and has a 98 percent first treatment shock success rate for resuscitating patients from SCA. To date, the LifeVest has been prescribed to more than 19,000 patients.
• STEMI solutions that enable hospitals to rapidly transmit data from the field into the cath lab to assist clinicians in meeting standards for door-to-balloon times.
• ZOLL’s complete line of professional defibrillators and AEDs featuring unique technologies including:
  • Real CPR Help^® feedback has been incorporated into all ZOLL defibrillators and AEDs to help rescuers provide high-quality manual CPR. This feedback technology features real-time auditory and visual feedback for gauging the rate and depth of CPR chest compressions.
  • See-Thru CPR^®, offered on the R Series, E Series^®, and AED Pro^®, is an industry-unique filtering technology that allows professional rescuers to view a patient’s underlying cardiac rhythm by filtering CPR artifact during resuscitation efforts. This may decrease CPR interruptions that were previously required to assess the cardiac rhythm.
• CodeNet^®, the first software system that allows hospital teams to better document, manage, and review cardiac arrest event and resuscitation information. CodeNet brings new improvements and efficiencies in data capture, event time synchronization, and case and aggregate reporting. It is the only system that time stamps logged events and synchronizes these times with defibrillator data, providing clinicians with a complete and accurate timeline of an entire cardiac arrest event.

Scientific Assembly Presentations

An education grant from ZOLL helps to underwrite the AHA Resuscitation Science Symposium (ReSS), an international forum for scientists and care providers to discuss recent advances related to treating cardiopulmonary arrest and life-threatening traumatic injury.

Sixteen scientific presentations related to ZOLL products and technology, including two that were recognized as "Best Presentations,” are scheduled. These studies cover ZOLL technology including Real CPR Help, See-Thru CPR, the AutoPulse, LifeVest, and therapeutic temperature management products. Many of these research projects were completed using the information provided by data products from ZOLL, including Code Review^® and RescueNet^®, that record clinical and operational information from all ZOLL devices and products.

A listing and schedule of the presentations is available at www.zoll.com/aha-presentations.

For copies of presentations or abstracts from ReSS, please access
http://scientificsessions.americanheart.org/portal/scientificsessions/ss/sessionsscienceondemand2009

About ZOLL Medical Corporation

ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company for the past three years, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.

Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are "forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled "Risk Factors” in the Company's Quarterly Report on Form 10-Q filed with the SEC on August 7, 2009. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.

Copyright © 2009 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL, AutoPulse, AED Plus, AED Pro, CodeNet, Code-Ready, E Series, LifeBand, LifeVest, PocketCPR, R Series, Real CPR Help, RescueNet, See-Thru CPR, and Thermogard XP are registered trademarks of ZOLL Medical Corporation. IVTM is a trademark of ZOLL Medical Corporation. All product names are the property of their respective owners.